Tuberculosis cases, TB deaths
To deliver on the Global Fund Strategy milestones
for 2028 and ensure we keep the SDG 3 target
within reach, we need to raise US$18 billion to
fund the Global Fund’s next three-year grant cycle.
An Overview of Current Evidence with Recommendations for Strengthening Community Health Worker Programs to Accelerate Progress in Achieving the Health-related Millennium Development Goals
Assessing the impact of the EVD outbreak on health systems in Sierra Leone. Survey concluded 6-17 October 2014
Country Progress Report January 2008 - December 2009
Tackling antimicrobial resistance- a story of a community playing its part.
This first volume of comic strips is titled "tackling antimicrobial resistance: a story of a community playing its part". It basically contains messages tailored for individuals at the grassroot.
A community-based approach.
These guidelines focus on manmade rather than natural disasters, but our experiences in India, El Salvador and Pakistan (earthquake interventions), and following the 2004 tsunami, cyclone Nargis in 2008 and the Haiti earthquake in 2010, showed that the principles describ...ed also work well in contexts of natural disasters.
more
Like the first volume, this one contains messages for the community but they are presented in a different version.
The WHO South-East Asia (SEA) Region bears a high burden of tuberculosis (TB) and MDR-TB. In 2015, the Region accounted for nearly 200 000 or 35% of the global estimated new RR/MDR-TB cases eligible for treatment. Extensively drug-resistant TB (XDRTB) has also been reported from s...ix countries of the SEA Region. MDR-TB could potentially replace drug-susceptible TB, and constitutes a threat to global public health security. The South- East Asia Regional Response Framework for DR-TB 2017–2021 complements the Ending TB in the South-East Asia Region: Regional Strategic Plan 2016–2020” and outlines key strategies for reducing morbidity, mortality and transmission of DR-TB.
more
The growing challenges for people in low and middle-income countries to access new medicines.
Analysis 58